A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells

Shingo Miyamoto, Ryo Iwamoto, Akiko Furuya, Kumiko Takahashi, Yuka Sasaki, Hiroshi Ando, Fusanori Yotsumoto, Tomoko Yoneda, Miki Hamaoka, Hiroshi Yagi, Takuya Murakami, Sayaka Hori, Kenya Shitara, Eisuke Mekada

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and plays a pivotal role in tumor progression in ovarian cancer. We developed an anti-HB-EGF monoclonal antibody (mAb) and investigated its antitumor activities in vitro and in vivo to evaluate its potential as a therapeutic antibody against ovarian cancer. Experimental Design: We prepared mAbs from HB-EGF null mice immunized with recombinant human soluble HB-EGF and evaluated their binding and neutralizing activity against HB-EGF. Next, we generated a mouse-human chimeric antibody and examined its in vitro and in vivo antitumor activities. Results: Two murine anti-HB-EGF mAbs were developed, and one of them, KM3566, was revealed to have a high binding reactivity for membrane-anchored HB-EGF (pro-HB-EGF) expressed on the cell surface, as well as neutralizing activity against growth promoting activity of soluble HB-EGF. The mouse-human chimeric counterpart for KM3566 (cKM3566) induced dose-dependent antibody-dependent cellular cytotoxicity (ADCC) against cancer cells expressing HB-EGF in vitro, and significantly inhibited tumor growth in severe combined immunodeficient mice inoculated with MCAS or ES-2 human ovarian cancer cells. Conclusions: A novel anti-HB-EGF chimeric antibody, cKM3566, with two antitumor mechanisms, neutralization and ADCC, exhibits potent in vivo antitumor activity. These results indicate that cKM3566 is a promising antiovarian cancer therapeutic antibody.

Original languageEnglish
Pages (from-to)6733-6741
Number of pages9
JournalClinical Cancer Research
Volume17
Issue number21
DOIs
Publication statusPublished - Nov 1 2011

Fingerprint

Epidermal Growth Factor
Ovarian Neoplasms
Monoclonal Antibodies
Antibodies
Neoplasms
SCID Mice
Heparin
Intercellular Signaling Peptides and Proteins
Research Design

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Miyamoto, S., Iwamoto, R., Furuya, A., Takahashi, K., Sasaki, Y., Ando, H., ... Mekada, E. (2011). A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. Clinical Cancer Research, 17(21), 6733-6741. https://doi.org/10.1158/1078-0432.CCR-11-1029

A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. / Miyamoto, Shingo; Iwamoto, Ryo; Furuya, Akiko; Takahashi, Kumiko; Sasaki, Yuka; Ando, Hiroshi; Yotsumoto, Fusanori; Yoneda, Tomoko; Hamaoka, Miki; Yagi, Hiroshi; Murakami, Takuya; Hori, Sayaka; Shitara, Kenya; Mekada, Eisuke.

In: Clinical Cancer Research, Vol. 17, No. 21, 01.11.2011, p. 6733-6741.

Research output: Contribution to journalArticle

Miyamoto, S, Iwamoto, R, Furuya, A, Takahashi, K, Sasaki, Y, Ando, H, Yotsumoto, F, Yoneda, T, Hamaoka, M, Yagi, H, Murakami, T, Hori, S, Shitara, K & Mekada, E 2011, 'A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells', Clinical Cancer Research, vol. 17, no. 21, pp. 6733-6741. https://doi.org/10.1158/1078-0432.CCR-11-1029
Miyamoto, Shingo ; Iwamoto, Ryo ; Furuya, Akiko ; Takahashi, Kumiko ; Sasaki, Yuka ; Ando, Hiroshi ; Yotsumoto, Fusanori ; Yoneda, Tomoko ; Hamaoka, Miki ; Yagi, Hiroshi ; Murakami, Takuya ; Hori, Sayaka ; Shitara, Kenya ; Mekada, Eisuke. / A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 21. pp. 6733-6741.
@article{dec5bbba85bd406ebc9542d6685c968b,
title = "A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells",
abstract = "Purpose: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and plays a pivotal role in tumor progression in ovarian cancer. We developed an anti-HB-EGF monoclonal antibody (mAb) and investigated its antitumor activities in vitro and in vivo to evaluate its potential as a therapeutic antibody against ovarian cancer. Experimental Design: We prepared mAbs from HB-EGF null mice immunized with recombinant human soluble HB-EGF and evaluated their binding and neutralizing activity against HB-EGF. Next, we generated a mouse-human chimeric antibody and examined its in vitro and in vivo antitumor activities. Results: Two murine anti-HB-EGF mAbs were developed, and one of them, KM3566, was revealed to have a high binding reactivity for membrane-anchored HB-EGF (pro-HB-EGF) expressed on the cell surface, as well as neutralizing activity against growth promoting activity of soluble HB-EGF. The mouse-human chimeric counterpart for KM3566 (cKM3566) induced dose-dependent antibody-dependent cellular cytotoxicity (ADCC) against cancer cells expressing HB-EGF in vitro, and significantly inhibited tumor growth in severe combined immunodeficient mice inoculated with MCAS or ES-2 human ovarian cancer cells. Conclusions: A novel anti-HB-EGF chimeric antibody, cKM3566, with two antitumor mechanisms, neutralization and ADCC, exhibits potent in vivo antitumor activity. These results indicate that cKM3566 is a promising antiovarian cancer therapeutic antibody.",
author = "Shingo Miyamoto and Ryo Iwamoto and Akiko Furuya and Kumiko Takahashi and Yuka Sasaki and Hiroshi Ando and Fusanori Yotsumoto and Tomoko Yoneda and Miki Hamaoka and Hiroshi Yagi and Takuya Murakami and Sayaka Hori and Kenya Shitara and Eisuke Mekada",
year = "2011",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-11-1029",
language = "English",
volume = "17",
pages = "6733--6741",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells

AU - Miyamoto, Shingo

AU - Iwamoto, Ryo

AU - Furuya, Akiko

AU - Takahashi, Kumiko

AU - Sasaki, Yuka

AU - Ando, Hiroshi

AU - Yotsumoto, Fusanori

AU - Yoneda, Tomoko

AU - Hamaoka, Miki

AU - Yagi, Hiroshi

AU - Murakami, Takuya

AU - Hori, Sayaka

AU - Shitara, Kenya

AU - Mekada, Eisuke

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Purpose: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and plays a pivotal role in tumor progression in ovarian cancer. We developed an anti-HB-EGF monoclonal antibody (mAb) and investigated its antitumor activities in vitro and in vivo to evaluate its potential as a therapeutic antibody against ovarian cancer. Experimental Design: We prepared mAbs from HB-EGF null mice immunized with recombinant human soluble HB-EGF and evaluated their binding and neutralizing activity against HB-EGF. Next, we generated a mouse-human chimeric antibody and examined its in vitro and in vivo antitumor activities. Results: Two murine anti-HB-EGF mAbs were developed, and one of them, KM3566, was revealed to have a high binding reactivity for membrane-anchored HB-EGF (pro-HB-EGF) expressed on the cell surface, as well as neutralizing activity against growth promoting activity of soluble HB-EGF. The mouse-human chimeric counterpart for KM3566 (cKM3566) induced dose-dependent antibody-dependent cellular cytotoxicity (ADCC) against cancer cells expressing HB-EGF in vitro, and significantly inhibited tumor growth in severe combined immunodeficient mice inoculated with MCAS or ES-2 human ovarian cancer cells. Conclusions: A novel anti-HB-EGF chimeric antibody, cKM3566, with two antitumor mechanisms, neutralization and ADCC, exhibits potent in vivo antitumor activity. These results indicate that cKM3566 is a promising antiovarian cancer therapeutic antibody.

AB - Purpose: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and plays a pivotal role in tumor progression in ovarian cancer. We developed an anti-HB-EGF monoclonal antibody (mAb) and investigated its antitumor activities in vitro and in vivo to evaluate its potential as a therapeutic antibody against ovarian cancer. Experimental Design: We prepared mAbs from HB-EGF null mice immunized with recombinant human soluble HB-EGF and evaluated their binding and neutralizing activity against HB-EGF. Next, we generated a mouse-human chimeric antibody and examined its in vitro and in vivo antitumor activities. Results: Two murine anti-HB-EGF mAbs were developed, and one of them, KM3566, was revealed to have a high binding reactivity for membrane-anchored HB-EGF (pro-HB-EGF) expressed on the cell surface, as well as neutralizing activity against growth promoting activity of soluble HB-EGF. The mouse-human chimeric counterpart for KM3566 (cKM3566) induced dose-dependent antibody-dependent cellular cytotoxicity (ADCC) against cancer cells expressing HB-EGF in vitro, and significantly inhibited tumor growth in severe combined immunodeficient mice inoculated with MCAS or ES-2 human ovarian cancer cells. Conclusions: A novel anti-HB-EGF chimeric antibody, cKM3566, with two antitumor mechanisms, neutralization and ADCC, exhibits potent in vivo antitumor activity. These results indicate that cKM3566 is a promising antiovarian cancer therapeutic antibody.

UR - http://www.scopus.com/inward/record.url?scp=80455140254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455140254&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-1029

DO - 10.1158/1078-0432.CCR-11-1029

M3 - Article

C2 - 21918176

AN - SCOPUS:80455140254

VL - 17

SP - 6733

EP - 6741

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -